Non-Hodgkin's Lymphoma: CALGB 50701 (Hematology Oncology Associates)

CALGB 50701 - A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND #101241) plus Rituximab in Previously Untreated Follicular Non-Hodgkin’s Lymphoma (NHL).


The purpose of this study is to find out what effects, good and/or bad, the
combination of epratuzumab and rituximab has on patients with non-Hodgkin's lymphoma (NHL). While rituximab is approved by the Food and Drug Administration (FDA) for treatment of follicular NHL that doesn’t respond to treatment or has come back after treatment, epratuzumab has not been approved by the FDA. The combination of epratuzumab with rituximab is experimental.

Epratuzumab is a variant of the naturally occurring antibody molecules the immune system uses to guard against infection. It is made in the laboratory, and has been effective in treating patients with relapsed lymphoma when given alone, and the combination of epratuzumab plus rituximab seemed even more effective when tested in the treatment of patients with follicular lymphoma who had recurrent disease. Neither epratuzumab nor rituximab is known to cause delayed bone marrow toxicity or increase patients’ risk for second malignancy.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Lymphoma
Cancer and Leukemia Group B
Katy D'Aprile, RN, BSN at 563-355-7733


  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office